【摘要】 目的:评估中药复方振明正生合剂对人肝癌、肺癌和大肠癌的抑制作用及其安全性。方法:Balb/c裸鼠分别接种人肝癌细胞系L7402、人肺癌细胞系A549和人大肠癌细胞SW4802×106/只。接种后24小时开始给药,实验组动物每天口服振明正生0.2ml/只,连续4周。对照组口服生理盐水0.2ml/只。每周测量实验组和对照组动物肿瘤大小,计算肿瘤生长抑制率。振明正生原液浓缩6倍,按照每只小鼠灌胃最大容量,口服浓缩药物0.6ml/20g。观察24小时,计算LD50。结果:振明正生对三种人肿瘤裸鼠移植瘤均有明显的抑制肿瘤生长的作用。经过3或4周的治疗,该中药对肝癌模型的抑制率超过79%(P<0.05),对大肠癌模型抑制率超过60%(P<0.05),对肺癌模型的抑制率达到41%(P<0.05)。LD50大于180ml/kg。结论:振明正生对这三种肿瘤模型具有显著的治疗作用,为无毒/低毒制剂。更多还原

【Abstract】 Objective:Inhibitive effects of Chinese herbal medicine, the "Zhenmingzhengsheng compound" (ZMZS) on human hepatocellular, lung and colon cancer were evaluated. Meanwhile its acute toxicity was observed. Methods: BALB/c nude mice were inoculated with human hepatoma cell line L7402, pulmonary cancer cell line A549 and colon cancer cell line SW480. 24 hours after inoculation, ZMZS was administered to the experiment mice (0.2ml/mouse), and saline to the control mice. The size of tumor was measured each week, and the inhibitive rate of tumor growth was calculated. The original liquid of ZMZS was concentrated to 1/6. According to the most dosage of a mouse can be received, the concentrates (0.6 ml/20g) was administered. The mice were observed during 24 houses, and LD50 was calculated. Results:The ZMZS has significant inhibitive effect on the tumor growth in the three models. After therapy of three to four weeks, the rates of inhibition respectively were 60%(P<0.05) and 41%(P<0.05) in liver cancer and lung cancer,LD50>180ml/kg. Conclusion:The ZMZS shows significant therapeutic effects in animal models of hepatocellular,lung and colon cancer. The acute toxicity test demostrated the ZMZS is safe.更多还原